Apollomics IncNASDAQ:APLMNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.4595
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots0.5070/ 1
- Ask / Lots0.5170/ 9
- Open / Previous Close0.0000 / 0.4595
- Day Range---
- 52 Week Range
- Volume383,363
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | APLM |
|---|---|---|
| 09:32 ET | 1264 | 0.478 |
| 09:36 ET | 100 | 0.478 |
| 09:41 ET | 3598 | 0.47 |
| 09:45 ET | 1500 | 0.47 |
| 09:54 ET | 100 | 0.47 |
| 09:59 ET | 1600 | 0.47 |
| 10:01 ET | 5409 | 0.47 |
| 10:06 ET | 8394 | 0.46 |
| 10:08 ET | 400 | 0.46 |
| 10:15 ET | 100 | 0.4637 |
| 10:21 ET | 1586 | 0.4655 |
| 10:28 ET | 1594 | 0.47 |
| 10:37 ET | 4448 | 0.465 |
| 10:46 ET | 8627 | 0.475 |
| 11:08 ET | 10371 | 0.475 |
| 11:20 ET | 87581 | 0.438 |
| 11:22 ET | 100 | 0.45 |
| 11:26 ET | 100 | 0.47 |
| 11:27 ET | 2500 | 0.44 |
| 11:29 ET | 5905 | 0.44 |
| 11:31 ET | 470 | 0.4332 |
| 11:33 ET | 100 | 0.44 |
| 11:42 ET | 295 | 0.4637 |
| 11:49 ET | 300 | 0.463 |
| 11:51 ET | 1230 | 0.4637 |
| 12:20 ET | 250 | 0.4401 |
| 12:52 ET | 1900 | 0.45 |
| 01:08 ET | 100 | 0.45 |
| 02:08 ET | 400 | 0.4637 |
| 02:09 ET | 400 | 0.4637 |
| 02:54 ET | 7821 | 0.45 |
| 02:56 ET | 230 | 0.454221 |
| 03:02 ET | 1940 | 0.45 |
| 03:23 ET | 200 | 0.477 |
| 03:39 ET | 1274 | 0.46 |
| 03:41 ET | 1354 | 0.4595 |
| 03:57 ET | 901 | 0.4595 |
| 03:59 ET | 1543 | 0.4595 |
Apr 10, 2024
Apollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting, from 7:00AM ET on Wednesday Apr 10, 2024 by Dow Jones
7:00AM ET on Wednesday Apr 10, 2024 by Dow Jones
Apr 2, 2024
Apr 1, 2024
DJ Apollomics Is Maintained at Buy by EF Hutton, from 8:48AM ET on Monday Apr 01, 2024 by Dow Jones
8:48AM ET on Monday Apr 01, 2024 by Dow JonesDJ Apollomics Is Maintained at Buy by HC Wainwright & Co., from 6:28AM ET on Monday Apr 01, 2024 by Dow Jones
6:28AM ET on Monday Apr 01, 2024 by Dow Jones
Mar 28, 2024
Press Release: Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results, from 7:00AM ET on Thursday Mar 28, 2024 by Dow Jones
7:00AM ET on Thursday Mar 28, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Apollomics Inc | 41.1M | -9.1x | --- |
Janone Inc | 41.1M | -1.4x | --- |
Estrella Immunopharma Inc | 41.0M | -0.6x | --- |
NextCure Inc | 40.2M | -0.6x | --- |
SensaSure Technologies Inc | 42.3M | -21.8x | --- |
NKGen Biotech Inc | 39.0M | -0.3x | --- |
Company Information
Apollomics Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies. The Company uses both targeted, immuno-oncology, and other approaches to address a range of cancer indications, such as acute myeloid leukemia, lung cancer, brain cancer, and other solid tumors. The product candidates in its pipeline are categorized into three groups based on their mechanisms of action, each of which contains product candidates at different stages of development: tumour inhibitors, anti-cancer enhancers, and immuno-oncology drugs. Its advanced product candidate is vebreltinib (APL-101), a potent, oral active, highly selective c-Met inhibitor. Its anti-cancer enhancer product candidates include uproleselan (APL-106) and are antagonists of a cell adhesion receptor called E-selectin. Its immuno-oncology product candidates consist of APL-501, APL-502, APL-801 and APL-810. Its other product candidates include APL-122, APL-102, and APL-108.
Contact Information
- Headquarters
- 989 East Hillsdale Blvd, Ste 220FOSTER CITY, CA, United States 94404
- Phone
- 650-209-4055
- Fax
- ---
Executives
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $41.1M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 89.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-0.05 |
Book Value | $9.36 |
P/E Ratio | -9.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
